Clinical Trial

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the neoantigen-based DC treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-02-19; most recent amendment 2025-02-25.
Status change: Not Yet Recruiting → Recruiting 2023-09-11
Trial Details
NCT Number NCT05749627
Lead Sponsor The First Affiliated Hospital of Nanchang University
Collaborators: Shanghai Dengding BioAI Co.
Conditions Advanced Malignant Solid Tumors
Enrollment 20 participants
Start Date 2023-04-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-27